Literature DB >> 28639139

Ex vivo permeation of erythropoietin through porcine conjunctiva, cornea, and sclera.

Ana Paula Resende1, Beatriz Silva2, Berta São Braz2, Telmo Nunes2, Lídia Gonçalves3, Esmeralda Delgado2.   

Abstract

The aim of this study is to test the permeation of human recombinant erythropoietin (rHuEPO) across conjunctiva, cornea, and sclera in an ex vivo model. Thirty fresh pig eyes were collected from a slaughterhouse. Conjunctivas (n = 10), corneas (n = 10), and scleras (n = 10) were surgically dissected from surrounding tissues. Ocular membranes were placed into Franz diffusion cells and rHuEPO was administered into the donor phase of each cell, except for control samples. Samples were collected from the receptor phase at seven time points, from 30 min to 6 h of incubation. Erythropoietin (EPO) was quantified by enzyme-linked immunosorbent assay (ELISA) technique. Ocular membranes immunohistochemistry was also performed at the end of the study. EPO was detected in all test samples. After 6 h of incubation, conjunctiva was the most permeable membrane to rHuEPO (509.3 ± 89.8 mIU/cm2, corresponding to 0.52% of the total rHuEPO administered on the donor phase), followed by sclera (359.1 ± 123.7 mIU/cm2, corresponding to 0.35%) and finally cornea (71.0 ± 31.8 mIU/cm2, corresponding to 0.07%). Differences between ocular membranes' permeation were statistically significant (p < 0.001). EPO immunostaining signal was positive for the three ocular membranes. We have demonstrated in an ex vivo model that porcine conjunctiva, cornea, and sclera are permeable to rHuEPO protein. These are promising results concerning ocular EPO administration.

Entities:  

Keywords:  Drug delivery; Erythropoietin; Ex vivo model; Ocular membranes

Mesh:

Substances:

Year:  2017        PMID: 28639139     DOI: 10.1007/s13346-017-0399-y

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  27 in total

Review 1.  Nanotechnology in ocular drug delivery.

Authors:  Sanjeeb K Sahoo; Fahima Dilnawaz; S Krishnakumar
Journal:  Drug Discov Today       Date:  2008-02       Impact factor: 7.851

2.  Permeation of proteins, oligonucleotide and dextrans across ocular tissues: experimental studies and a literature update.

Authors:  Silvia Pescina; Paolo Govoni; Maxim Antopolsky; Lasse Murtomäki; Cristina Padula; Patrizia Santi; Sara Nicoli
Journal:  J Pharm Sci       Date:  2015-05-13       Impact factor: 3.534

3.  Landmark advances in the development of erythropoietin.

Authors:  James W Fisher
Journal:  Exp Biol Med (Maywood)       Date:  2010-12

4.  Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice.

Authors:  Lichun Zhong; John Bradley; William Schubert; Ednan Ahmed; Anthony P Adamis; David T Shima; Gregory S Robinson; Yin-Shan Ng
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-03       Impact factor: 4.799

Review 5.  Ocular delivery of macromolecules.

Authors:  Yoo Chun Kim; Bryce Chiang; Xianggen Wu; Mark R Prausnitz
Journal:  J Control Release       Date:  2014-07-03       Impact factor: 9.776

6.  Alternative route for erythropoietin ocular administration.

Authors:  Ana Paula Resende; Berta São-Braz; Esmeralda Delgado
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-05-24       Impact factor: 3.117

7.  Characterization of human sclera barrier properties for transscleral delivery of bevacizumab and ranibizumab.

Authors:  He Wen; Jinsong Hao; S Kevin Li
Journal:  J Pharm Sci       Date:  2012-12-04       Impact factor: 3.534

Review 8.  Revisiting the role of erythropoietin for treatment of ocular disorders.

Authors:  S L Shirley Ding; S N Leow; R Munisvaradass; E H Koh; M L C Bastion; K Y Then; S Kumar; P L Mok
Journal:  Eye (Lond)       Date:  2016-06-10       Impact factor: 3.775

Review 9.  Evidence That Erythropoietin Modulates Neuroinflammation through Differential Action on Neurons, Astrocytes, and Microglia.

Authors:  Wesley S Bond; Tonia S Rex
Journal:  Front Immunol       Date:  2014-10-22       Impact factor: 7.561

Review 10.  Erythropoietin in ophthalmology: A literature review.

Authors:  Kaveh Abri Aghdam; Mostafa Soltan Sanjari; Khalil Ghasemi Falavarjani
Journal:  J Curr Ophthalmol       Date:  2016-03-30
View more
  5 in total

1.  Optimization, Biopharmaceutical Profile and Therapeutic Efficacy of Pioglitazone-loaded PLGA-PEG Nanospheres as a Novel Strategy for Ocular Inflammatory Disorders.

Authors:  Marcelle Silva-Abreu; Ana Cristina Calpena; Marta Espina; Amelia M Silva; Alvaro Gimeno; María Antonia Egea; María Luisa García
Journal:  Pharm Res       Date:  2018-01-03       Impact factor: 4.200

2.  Role of mucoadhesive agent in ocular delivery of ganciclovir microemulsion: cytotoxicity evaluation in vitro and ex vivo.

Authors:  Manisha Choudhari; Kritika Nayak; Noriaki Nagai; Yosuke Nakazawa; Dignesh Khunt; Manju Misra
Journal:  Int Ophthalmol       Date:  2022-09-26       Impact factor: 2.029

3.  Functional and Structural Effects of Erythropoietin Subconjunctival Administration in Glaucomatous Animals.

Authors:  Ana Paula Resende; Serge G Rosolen; Telmo Nunes; Berta São Braz; Esmeralda Delgado
Journal:  Biomed Hub       Date:  2018-07-13

4.  Chitosan and Hyaluronic Acid Nanoparticles as Vehicles of Epoetin Beta for Subconjunctival Ocular Delivery.

Authors:  Beatriz Silva; Lídia M Gonçalves; Berta São Braz; Esmeralda Delgado
Journal:  Mar Drugs       Date:  2022-02-18       Impact factor: 5.118

5.  PPARγ agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer's disease: in vitro and in vivo studies.

Authors:  Marcelle Silva-Abreu; Ana Cristina Calpena; Pol Andrés-Benito; Ester Aso; Ignacio A Romero; David Roig-Carles; Radka Gromnicova; Marta Espina; Isidre Ferrer; María Luisa García; David Male
Journal:  Int J Nanomedicine       Date:  2018-09-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.